Index of artpub/2022/282285/

Herbst, Roy S
COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
2022
https://ddd.uab.cat/record/282285